China to make 100m AstraZeneca Covid-19 vaccine doses by Xmas – Wall Street Journal

In an effort to stop the spread of Covid-19, the University of Oxford has been developing the Oxford vaccine in collaboration with biopharmaceutical company AstraZeneca. In 2015, the disruptive South African financial services company, Sygnia, bought shares in Oxford Sciences Innovation (OSI), a company that transforms patents from Oxford University into viable businesses for 25% ownership. In a recent interview, Sygnia co-founder Magda Wierzycka told BizNews founder Alec Hogg that the vaccine has an 80% chance of success. "They predict that it will be a two-dose vaccine," she explains, "and it will be annual." According to National Geographic, the preliminary results from all volunteer trials will be collected through November. If the vaccine is effective, it will be submitted for registration with the Medicines and Healthcare products Regulatory Agency (MHRA) by the end of 2020. – Claire Badenhorst 

AstraZeneca strikes deal to produce Covid-19 vaccine for China

By Chao Deng and Joseph Walker

AstraZeneca PLC has agreed to have a Chinese drugmaker produce hundreds of millions of doses of its experimental Covid-19 vaccine for use in China if it is approved by regulators there, a deal that expands China's access to potential vaccine options.

___STEADY_PAYWALL___